In Short: Shareholders of Taro Pharmaceutical Industries approved a merger with Sun Pharmaceutical Industries, ending a 10-year feud. Sun Pharma will acquire all Taro shares for $43 each. Taro will become private and delist from NYSE. The merger aims to better serve patients and compete in the market. Taro’s recent financial performance showed increased sales […]This news is sourced from India Telecom News.

More...